黄龙华盖饮治疗咳嗽变异型哮喘的临床效果  

Clinical effects of Huanglong Huagai Yin on cough variant asthma

作　　者：肖国红 陈传铭 张玉卿 Xiao Guohong

机构地区：[1]广州市白云区第二人民医院

出　　处：《中医临床研究》2019年第14期121-123,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:探讨咳嗽变异型哮喘实施黄龙华盖饮治疗的临床疗效。方法:择本科室2016年9月-2017年9月间80例咳嗽变异型哮喘患者,借助SAS8.2统计软件生成试验病例随机数字表进行分组:试验组(54例)、对照组(26例),试验组口服黄龙华盖饮治疗,对照组口服顺尔宁+吸入信必可都保治疗,对比不同方案下患者治疗总有效率、支气管激发试验、肺功能、免疫学指标、用药安全性状况。结果:试验组患者治疗总有效率较对照组明显升高(P<0.05),且试验组患者治疗后支气管激发试验(PD20-FEV1)、一秒用力呼气容积(FEV1)、用力肺活量(Forced Vital Capacity,FVC)较对照组明显升高,嗜酸性粒细胞(Eosinophil,EOS)、血清免疫球蛋白E(IgE)较对照组明显降低(P<0.05)。试验组无不良反应,对照组出现2例咽部不适。试验组6个月复发率较对照组明显降低(P<0.05)。结论:咳嗽变异型哮喘实施黄龙华盖饮治疗可达到良好的疗效。Objective: To evaluate the clinical efficacy of Huanglong Huagai Yin (黄龙华盖饮) on cough variant asthma. Methods: 80 patients were divided into the experimental group (54 cases) and the control group (26 cases). The experimental group was treated with Huanglong Huagai Yin;the control group was treated with Singulair plus symbicort turbuhaler. The total efficiency, bronchial provocation test, lung function, immunological indicators and medication were compared in groups. Results: The total efficiency in the experimental group was significantly higher than the control group (P<0.05). The PD20-FEV1, FEV1, and FVC in the experimental group were significantly higher than the control group;and the EOS and IgE were significantly lower than the control group (P<0.05). There were no adverse reactions in the experimental group;2 cases were pharyngeal discomfort in the control group. The 6-month recurrence rate in the experimental group was significantly lower than the control group (P<0.05). Conclusion: Huanglong Huagai Yin on cough variant asthma shows good effects.

关 键 词：咳嗽变异型哮喘 黄龙华盖饮 临床疗效 

分 类 号：R256.12[医药卫生—中医内科学]